Chr del(11q)

News alerts, weekly reports and conference planners

Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	rituximab Resistant: A2 - Guideline rituximab Resistant : A2	rituximab Resistant: A2 - Guideline rituximab Resistant : A2
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B	ibrutinib + ublituximab-xiiy Sensitive: B - Late Trials ibrutinib + ublituximab-xiiy Sensitive : B
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
Chr del(11q)	Small Lymphocytic Lymphoma	Chr del(11q)	Small Lymphocytic Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
Chr del(11q)	Small Lymphocytic Lymphoma	Chr del(11q)	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: C2 – Inclusion Criteria venetoclax + ibrutinib Sensitive : C2	venetoclax + ibrutinib Sensitive: C2 – Inclusion Criteria venetoclax + ibrutinib Sensitive : C2
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	lenalidomide + tafasitamab-cxix Sensitive: C3 – Early Trials lenalidomide + tafasitamab-cxix Sensitive : C3	lenalidomide + tafasitamab-cxix Sensitive: C3 – Early Trials lenalidomide + tafasitamab-cxix Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
Chr del(11q)	Small Lymphocytic Lymphoma	Chr del(11q)	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
Chr del(11q)	Multiple Myeloma	Chr del(11q)	Multiple Myeloma	obinutuzumab Resistant: C3 – Early Trials obinutuzumab Resistant : C3	obinutuzumab Resistant: C3 – Early Trials obinutuzumab Resistant : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3	duvelisib Sensitive: C3 – Early Trials duvelisib Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	ibrutinib + UC-961 Sensitive: C3 – Early Trials ibrutinib + UC-961 Sensitive : C3	ibrutinib + UC-961 Sensitive: C3 – Early Trials ibrutinib + UC-961 Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	Compound C Sensitive: D – Preclinical Compound C Sensitive : D	Compound C Sensitive: D – Preclinical Compound C Sensitive : D
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	MRT68921 Sensitive: D – Preclinical MRT68921 Sensitive : D	MRT68921 Sensitive: D – Preclinical MRT68921 Sensitive : D

Chr del(11q)

Associations